2025 Latin America Antibodies Contract Manufacturing Revenue Opportunities Report
Description
The 2025 Latin America Antibodies Contract Manufacturing Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in antibody contract manufacturing in Latin America include Lonza Group Ltd., Catalent Inc., Boehringer Ingelheim, and Thermo Fisher Scientific (Patheon Inc.). These firms are global leaders in biopharmaceutical contract development and manufacturing, offering advanced capabilities in monoclonal antibody (mAb) production, which dominates the regional market. Lonza and Catalent lead with extensive manufacturing capacity and strategic partnerships supporting biosimilar and innovative antibody therapies in key countries such as Brazil, Mexico, and Argentina. Boehringer Ingelheim and Thermo Fisher Scientific also hold significant presence, leveraging advanced bioprocessing technologies to meet rising regional demand for affordable biologics.
Additionally, other major multinational pharma companies, such as Roche, Bristol-Myers Squibb, Merck & Co., and Johnson & Johnson, have substantial market shares through their integrated manufacturing and commercialization of mAbs and biosimilars targeted at cancer and autoimmune indications. Local companies like Biosidus in Argentina focus on biosimilars production, aiming to expand access and reduce treatment costs in Latin America. The region is rapidly growing, with the biosimilars market expected to exceed multi-billion dollar valuations by 2025, driven by higher R&D investments and supportive government policies for biologics manufacturing.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibodies Contract Manufacturing by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in antibody contract manufacturing in Latin America include Lonza Group Ltd., Catalent Inc., Boehringer Ingelheim, and Thermo Fisher Scientific (Patheon Inc.). These firms are global leaders in biopharmaceutical contract development and manufacturing, offering advanced capabilities in monoclonal antibody (mAb) production, which dominates the regional market. Lonza and Catalent lead with extensive manufacturing capacity and strategic partnerships supporting biosimilar and innovative antibody therapies in key countries such as Brazil, Mexico, and Argentina. Boehringer Ingelheim and Thermo Fisher Scientific also hold significant presence, leveraging advanced bioprocessing technologies to meet rising regional demand for affordable biologics.
Additionally, other major multinational pharma companies, such as Roche, Bristol-Myers Squibb, Merck & Co., and Johnson & Johnson, have substantial market shares through their integrated manufacturing and commercialization of mAbs and biosimilars targeted at cancer and autoimmune indications. Local companies like Biosidus in Argentina focus on biosimilars production, aiming to expand access and reduce treatment costs in Latin America. The region is rapidly growing, with the biosimilars market expected to exceed multi-billion dollar valuations by 2025, driven by higher R&D investments and supportive government policies for biologics manufacturing.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
